(PharmaNewsWire.Com, May 12, 2017 ) “Asia-Pacific Cancer Monoclonal Antibodies” research report published by Market Data Forecast estimates that the market is growing with a CAGR of 13.5% to reach USD 8.14 billion by 2021, from USD 4.32 billion in 2016, which amounts to a cumulative growth of USD 3.82 billion.
Cancer is the leading cause of death across the globe currently. It starts from a single cell in the body genetically transforming a normal cell to a tumour and is eventually spread to other cells. Typically, drugs and chemotherapy are used as a treatment to cure cancer. The adverse side effect that comes with them has made the pharmaceutical companies to concentrate on monoclonal antibodies.
Cancer Monoclonal Antibodies Market have the ability to offer less toxic and more efficient therapeutic alternatives to treat the disease. Recent years have seen the emergence of monoclonal antibodies being used to treat wide array of diseases that are related to cancer. These antibodies are mono-specific comprising of identical immune cells, which are clones of a single parent cell and are directed towards a specific cellular target. Thus, monoclonal antibodies due to its customizable nature can be used to treat the cancerous cells not affecting the normal ones.
The report also presents detailed analysis of multitude of factors affecting Asia-Pacific Cancer Monoclonal Antibodies bearing either positive or negative outcomes. Some of those factors are
• With the increase in the cases of cancer in the recent past, the pharmaceutical companies have started investing aggressively in monoclonal antibodies.
• Increased investment in R&D for genomic studies,
• Specificity to target only the cancer cell by monoclonal antibodies
• Technological evolvement in genetic sequencing and target gene selection
• High costs of development
• Longer durations required for clinical trials and research & development of antibodies
For granular level understanding, the Asia-Pacific Cancer Monoclonal Antibodies Market is segmented based on product, type, Conjugated Cancer therapies each being provided with Market Size Estimations and Y-o-Y Forecasts. The Asia-Pacific Monoclonal Antibodies Market is divided based on its application as Breast, liver, Brain, Blood, colorectal, leukaemia, Hodgkins & Non-Hodgkins and others. The market is further analysed on the basis of type as fully humanized antibodies, murine antibodies and chimeric & humanised antibodies. The market based on Conjugated Cancer therapies is segmented as Immunocytokines, ADEPT, Radioimmunotherapy and Immunoliposome.
The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea, and Australia. Developing countries in this region such as India and China are projected to witness significant growth in the Plant Growth Regulators market due to the large-scale cotton industries and increasing acceptance of sustainable farming in this region.
The key players in Asia-Pacific Cancer Monoclonal Antibodies Market include Amgen, Bristol Myers Squibb, Eli Lilly, Roche, Immunogen, Novartis, Glaxosmithkline, Genmab, Seattle Genetics and Spectrum Pharaceuticals. According to a study published by NCBI at the end of 2016, approximately 816 companies were involved in therapeutic protein research.
The Asia-Pacific Cancer Monoclonal Antibodies Market report offers wide-range of scope:
• Regional and country-level analysis that provides an individual perspective of Asia-Pacific region and the aforementioned countries
• Know more about key areas of industry growth via detailed Segment-level analysis on basis of product, type, Conjugated Cancer therapies with market size forecasts and y-o-y estimations
• Detailed explanation of major drivers, restraints, opportunities, and challenges (DROC) that affect the market and impact the ever-shifting market dynamics
• Strategic Analyses containing PESTLE and Porter’s Five Forces Analyses which are obtained by studying the macro & micro environmental factors that affect the market demographics
• Comprehensive listing of key market players along with Company overview, product portfolios, financials (subjected to availability), SWOT analysis and analyst overview
• Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
• Market Outlook - Investment opportunities devised by stand in experts to provide both individuals and organizations a strong financial foothold in the market
For more reports related to the Asia-Pacific Cancer Monoclonal Antibodies Market:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
